Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3743063015 | Tildrakizumab only product in parenteral dose form | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3743064014 | Product containing only tildrakizumab in parenteral dose form (medicinal product form) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 1136521000172111 | produit contenant seulement du tildrakizumab sous forme parentérale | fr | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | Belgian module (core metadata concept) |
| 1229351000172118 | product dat enkel tildrakizumab in parenterale vorm bevat | nl | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | Belgian module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Tildrakizumab only product in parenteral dose form | Count of base of active ingredient | 1 | false | Inferred relationship | Some | ||
| Tildrakizumab only product in parenteral dose form | Is a | Product containing tildrakizumab in parenteral dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Tildrakizumab only product in parenteral dose form | Is a | Product containing only tildrakizumab (medicinal product) | true | Inferred relationship | Some | ||
| Tildrakizumab only product in parenteral dose form | Has active ingredient | Tildrakizumab (substance) | true | Inferred relationship | Some | 1 | |
| Tildrakizumab only product in parenteral dose form | Has manufactured dose form | Parenteral dose form (dose form) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Tildrakizumab 100 mg/mL solution for injection | Is a | True | Tildrakizumab only product in parenteral dose form | Inferred relationship | Some |
This concept is not in any reference sets
FHIR